Bluejay Diagnostics, Inc. BJDX
is a medical diagnostics company focused on improving patient outcomes in critical care settings, with a focus on sepsis. We are working
on developing rapid, near-patient tests using whole blood on our Symphony technology platform ("Symphony"), which consists
of an analyzer and single-use protein detection cartridges. We do not yet have regulatory clearance for Symphony, and we will need to
receive regulatory authorization from the U.S. Food and Drug Administration (the "FDA") before Symphony can be marketed as
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $249.0K | — | — | — |
| Cost of revenue | — | — | — | $200.1K | — | — | — |
| Gross profit | — | — | — | $48.9K | — | — | — |
| R&D | $3.0M | $3.5M | $5.7M | $4.2M | $1.1M | $527.3K | — |
| SG&A | $3.9M | $3.7M | $4.3M | $451.4K | $1.8M | $596.1K | — |
| Total operating expenses | $7.0M | $7.2M | $10.3M | $9.4M | $3.2M | $1.2M | — |
| Operating income | -$7.0M | -$7.2M | -$10.3M | -$9.3M | -$3.2M | -$1.2M | — |
| Interest expense | $839 | $823.0K | — | — | $6.4K | $27.0K | — |
| Net income | -$6.8M | -$7.7M | -$10.0M | -$9.3M | -$3.5M | -$1.2M | — |
| EPS, basic | -15.25 | -456.75 | -3,631.48 | -9.22 | -0.41 | — | — |
| EPS, diluted | -15.25 | -456.75 | -3,631.48 | -9.22 | -0.41 | -0.37 | — |
| Shares, diluted (wtd. avg.) | 449,043 | 45,848 | 2,741 | 1.0M | 8.5M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.2M | $4.3M | $2.2M | $10.1M | $19.0M | $912.4K | $96.0K |
| Inventory | — | — | — | — | — | $84.8K | — |
| Total current assets | $5.5M | $4.9M | $3.2M | $11.8M | $20.7M | $1.1M | — |
| Property, plant and equipment | $1.5M | $1.5M | $1.3M | $1.2M | $337.4K | $459.1K | — |
| Total assets | $7.1M | $6.7M | $4.9M | $13.5M | $21.0M | $1.5M | — |
| Accounts payable | $214.3K | $145.1K | $491.5K | $635.8K | $295.8K | $374.9K | — |
| Total current liabilities | $1.1M | $810.4K | $1.8M | $1.6M | $637.2K | — | — |
| Total liabilities | $1.1M | $927.9K | $2.0M | $2.0M | $637.2K | $1.8M | — |
| Retained earnings | -$41.5M | -$34.7M | -$27.0M | -$17.0M | -$7.7M | -$4.2M | — |
| Total equity | $6.0M | $5.7M | $2.9M | $11.5M | $20.4M | -$4.2M | -$2.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.1M | -$7.8M | -$8.3M | -$7.7M | -$4.4M | -$508.7K | — |
| Depreciation and amortisation | $74.2K | $75.6K | $648.7K | $156.6K | — | — | — |
| Stock-based compensation | $6 | $20.1K | $189.2K | $433.0K | $68.5K | $3.7K | — |
| Capital expenditure | $173.7K | $306.8K | $704.2K | $1.2M | $23.9K | — | — |
| Investing cash flow | -$173.7K | -$306.8K | -$704.2K | -$1.2M | -$23.9K | — | — |
| Financing cash flow | $7.1M | $10.2M | $1.1M | $8.1K | $22.5M | $1.3M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-024616.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $249.0K | — | — | — |
| Gross profit | — | — | — | $48.9K | — | — | — |
| Net income | — | -$1.2M | -$3.5M | -$9.3M | -$10.0M | -$7.7M | -$6.8M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed Item 1.01
- Regulation FD disclosure Item 7.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Item 7.01
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |